Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042180 | 0.87 | MAPT (0.40) | SCN9ACYP3A4CTSSCTSKEPHX2 | |
| SCHEMBL7043390 | 0.85 | SCN9A (0.31) | SCN9ASCN10ACYP3A4EPHX2 | |
| SCHEMBL7043387 | 0.82 | XDH (0.31) | — | |
| SCHEMBL6061805 | 0.78 | RAB9A (0.32) | CTSS | |
| SCHEMBL7044363 | 0.77 | PPARG (0.49) | SCN9ACYP3A4CTSSCTSKEPHX2 | |
| SCHEMBL6061798 | 0.77 | RAB9A (0.32) | CTSS | |
| SCHEMBL6468723 | 0.76 | THRB (0.31) | CTSS | |
| SCHEMBL6633837 | 0.74 | CTSS (0.45) | SCN9ACTSSCTSKMMP13CACNA1B | |
| SCHEMBL6633834 | 0.74 | CTSS (0.45) | SCN9ACTSSCTSKMMP13CACNA1B | |
| SCHEMBL6466324 | 0.74 | CTSS (0.38) | CYP3A4CTSSCTSKEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | SCN9A 2740/4885SCN10A 3158/4885CYP3A4 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.